Stephan Dickgiesser

Title: The Innovations of Stephan Dickgiesser

Introduction

Stephan Dickgiesser is a notable inventor based in Darmstadt, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of engineered antigen-binding molecules. His work has implications for therapeutic applications and advances in medical science.

Latest Patents

Stephan Dickgiesser holds a patent for "Cysteine engineered antigen-binding molecules." This patent describes a specific antigen-binding member (ABM) that includes a specific antigen-binding moiety and an antibody Fc region. The Fc region is engineered for a cysteine substitution at positions 108 and/or 113, according to the IMGT numbering system. Notably, the antibody Fc region does not include an antigen-binding CH3 domain. Additionally, the patent covers an ABM conjugate (ABMC) that comprises the ABM and at least one heterologous molecule covalently conjugated to one or both of the cysteines at positions 108 and 113 of the CH2 domain. This innovation represents a significant advancement in the design of therapeutic agents.

Career Highlights

Stephan Dickgiesser is associated with Merck Patent GmbH, where he continues to contribute to innovative research and development. His expertise in the field has led to the creation of valuable intellectual property that enhances the capabilities of therapeutic interventions.

Collaborations

Throughout his career, Stephan has collaborated with esteemed colleagues such as Florian Rüker and Gordana Wozniak-Knopp. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and the advancement of scientific knowledge.

Conclusion

Stephan Dickgiesser's work exemplifies the spirit of innovation in biotechnology. His patent for cysteine engineered antigen-binding molecules showcases his commitment to advancing medical science. Through his contributions, he continues to impact the field positively.